Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.

Zhou S, Patel V, Kishi N, Akhtar K, Tsao CK

Open source

DOI
10.1080/1750743x.2026.2722581
Published
2026 Aug 25
Container
Immunotherapy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/1750743x.2026.2722581,
  title = {Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.},
  author = {Zhou S and Patel V and Kishi N and Akhtar K and Tsao CK},
  year = {2026},
  journal = {Immunotherapy},
  doi = {10.1080/1750743x.2026.2722581},
  url = {https://doi.org/10.1080/1750743x.2026.2722581}
}

RIS

TY  - JOUR
TI  - Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.
AU  - Zhou S
AU  - Patel V
AU  - Kishi N
AU  - Akhtar K
AU  - Tsao CK
PY  - 2026
JO  - Immunotherapy
DO  - 10.1080/1750743x.2026.2722581
UR  - https://doi.org/10.1080/1750743x.2026.2722581
ER  - 

APA

S, Z., V, P., N, K., K, A., & CK, T. (2026). Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.. Immunotherapy. https://doi.org/10.1080/1750743x.2026.2722581

Source records